Hypertension is associated with oral, laryngeal, and esophageal cancer: a nationwide population-based study

Jae-Hyun Seo, Young-Du Kim, Chan-Seok Park, Kyung-do Han & Young-Hoon Joo

Several studies have reported an association between hypertension and upper aerodigestive tract cancer, but no large-scale, population-based studies have been conducted to confirm this. The aim of this study was to explore the association between hypertension and risk of upper aerodigestive tract cancer in Koreans. Participants who underwent a national health screening examination from January 1 to December 31, 2009 (n = 9,746,606) were enrolled. We assessed the development of oral, laryngeal, or esophageal cancer until 2016 using records from the Korean Health Insurance claims database during the study period. During the seven-year follow-up period, 6,062, 2,658, and 4,752 subjects were newly diagnosed with oral, laryngeal, and esophageal cancer, respectively. Participants with metabolic syndrome had the highest risk of developing oral cancer (hazard ratio (HR) 1.09, 95% confidence interval (CI) 1.03–1.16), laryngeal cancer (HR 1.27, 95% CI 1.17–1.38), and esophageal cancer (HR 1.11, 95% CI 1.04–1.19). Hypertension was a remarkable risk factor for each cancer (HR 1.11, 95% CI 1.04–1.17 for oral cancer; HR 1.23, 95% CI 1.13–1.33 for laryngeal cancer; HR 1.25, 95% CI 1.18–1.33 for esophageal cancer) after adjusting for age and other variables including gender, smoking status, alcohol intake, exercise, body mass index, and diabetes. Patients with untreated hypertension were at highest risk of developing oral cancer (HR 1.15; 95% CI 1.05–1.26), laryngeal cancer (HR 1.25; 95% CI 1.09–1.44), and esophageal cancer (HR 1.47; 95% CI 1.33–1.63) after adjusting for confounders. Hypertension was associated with the risk of oral, laryngeal, and esophageal cancer, despite of the lack of detailed biochemical information including the cancer cell types (squamous cell carcinoma or adenocarcinoma), cancer stage, physical findings and other medical history. Further studies are warranted to determine the reasons for this association and to establish effective interventions in this vulnerable population.

One million new cases of upper aerodigestive tract (UADT) cancers are diagnosed worldwide every year, and they are ranked among the top ten most common cancers. Malignant tumors of the oral cavity, oropharynx, larynx, and esophagus comprise almost (or more than) 90% of all cancers of the UADT. Most of these cancers are histologically squamous cell carcinoma. Although the UADT is not considered a vital organ, it is closely associated with quality of life as it relates to eating, breathing, and speaking. Malignancies of this organ are therefore highly...
morbid. As with all other malignant tumors, identifying and minimizing risk factors for UADT cancer development is essential. Alcohol consumption and tobacco smoking are well known risk factors for these cancers1,2. Metabolic syndrome (MetS) is a cluster of metabolic abnormalities associated with insulin resistance, including obesity, hypertension, hyperglycemia, dyslipidemia, and elevated triglyceride levels3. MetS is closely linked to cancer, as it increases cancer risk and cancer-related mortality3. Early diagnosis of MetS is crucial in those with malignant tumors. The incidence of MetS is gradually increasing in Korean adults. Since there are reports that MetS is correlated with the occurrence of malignant tumors, we must verify the relationship between MetS and cancer development through population studies4.

Hypertension is the most prevalent adult disease in South Korea, affecting 7.8% of Korean adults5. In 2017, US guidelines for hypertension changed the definition of hypertension from the general accepted level of 140/90 mmHg to 130/80 mmHg6. However, the recently announced Korean hypertension guidelines maintained 140/90 mmHg as the definition criteria of hypertension7. Many studies have separately reported hypertension as an important risk factor for rising cancer incidence and mortality. Hypertension is an independent risk factor of renal cell carcinoma based on prospective cohort study8. In addition, the results from other large prospective studies reported positive associations of hypertension with the risk of cancers in locations other than the kidney in men (oropharynx, colon, rectum and anus, lung with larynx and trachea, bladder, malignant melanoma and non‐melanoma skin cancer)9. The meta-analysis of four prospective studies between hypertension and esophageal adenocarcinoma yielded a statistically significant positive association10. Most recently, Christakoudi et al. reported that there was a positive correlation between blood pressure and risk of esophageal carcinoma and head and neck cancers in a prospective European study11. However, there have been no large-scale, population-based studies investigating whether hypertension increases the risk of developing UADT cancers. The objective of this study was to determine the effect of hypertension on the development of oral, laryngeal, and esophageal cancer in a Korean population.

### Results

#### Basic characteristics.

Baseline characteristics of the population are summarized in Table 1. The mean age of those with hypertension was significantly higher than that of those without hypertension (56.57 years vs. 43.59 years, p < 0.0001). The baseline percentage of male participants with hypertension was 56.96% and the percentage of those without hypertension was 54.26% (p < 0.0001). Current smoking, heavy drinking, diabetes, and dyslipidemia were significantly more frequent in the hypertension groups at baseline. Participants with hypertension had significantly higher body mass index, mean waist circumferences, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose levels, and fasting total cholesterol levels than those without hypertension (p < 0.0001).

#### Association of MetS with oral, laryngeal, and esophageal cancers.

During the seven-year follow-up period, 6,062, 2,658, and 4,752 subjects were newly diagnosed with oral, laryngeal, and esophageal cancers, respectively. We analyzed the effect of MetS at baseline on the risk of each cancer (Table 2). Age, gender, smoking status, alcohol intake, exercise, and body mass index-adjusted hazard ratios indicate that participants with MetS had a higher risk of developing each cancer (hazard ratio (HR) 1.09, 95% confidence intervals (CI) 1.03–1.16 for oral cancer, HR 1.27, 95% CI 1.17–1.38 for laryngeal cancer, and HR 1.11, 95% CI 1.04–1.19 for esophageal cancer) than did those without MetS. The number of MetS components was found to be a strong risk factor, with a higher risk estimate of oral, laryngeal, and esophageal cancers.

| Parameter          | Yes (n = 2,481,444) | No (n = 7,265,162) | P-value  |
|--------------------|---------------------|--------------------|----------|
| Age (years)        | 56.57 ± 12.80       | 43.59 ± 12.87      | <0.0001* |
| Gender (male)      | 1,413,350 (56.96%)  | 3,942,240 (52.26%) | <0.0001* |
| Smoking (current smoker) | 2,022,811 (27.84%) | 555,105 (22.37%)  | <0.0001* |
| Drinking (heavy drinker) | 203,531 (8.2%)    | 470,834 (6.48%)   | <0.0001* |
| Routine exercise   | 1,210,766 (48.79%)  | 3,805,517 (52.38%) | <0.0001* |
| Place (urban)      | 1,349,490 (54.38%)  | 3,913,772 (53.87%) | <0.0001* |
| Diabetes           | 477,770 (19.25%)    | 357,521 (4.92%)    | <0.0001* |
| Dyslipidemia       | 820,382 (33.06%)    | 951,895 (13.1%)    | <0.0001* |
| Body mass index (kg/m²) | 25.03 ± 3.22       | 23.26 ± 3.07       | <0.0001* |
| Waist circumference (cm) | 84.56 ± 8.45       | 78.73 ± 8.80       | <0.0001* |
| Systolic BP (mmHg) | 136.34 ± 15.58      | 117.62 ± 11.26     | <0.0001* |
| Diastolic BP (mmHg) | 84.54 ± 10.76       | 73.48 ± 7.92       | <0.0001* |
| Glucose (mmol/L)   | 5.82 ± 1.61         | 5.24 ± 1.09        | <0.0001* |
| Total cholesterol (mmol/L) | 5.17 ± 1.00        | 5.00 ± 0.93        | <0.0001* |

Table 1. Analysis of factors potentially associated with hypertension (n = 9,746,606). Values are mean ± SE or % ± SE. *Significant at p < 0.05.
Association of hypertension with oral, laryngeal, and esophageal cancers. The relationship between hypertension and the risk of oral, laryngeal and esophageal cancers was linear as shown in Figure 1. Hypertension was significantly associated with an increased risk of each cancer. Table 3 shows results of Cox proportional hazards analyses after adjusting for age and other variables including gender, smoking status, alcohol intake, exercise, body mass index, and diabetes for each cancer. Hypertension was a notable risk factor for each cancer after adjusting for confounders (HR 1.11, 95% CI 1.04–1.17 for oral cancer; HR 1.23, 95% CI 1.13–1.33 for laryngeal cancer; HR 1.25, 95% CI 1.18–1.33 for esophageal cancer). When participants were divided according to gender or smoking status, the risk of developing each cancer was significantly associated with hypertension in men (HR 1.14, 95% CI 1.06–1.21 for oral cancer, HR 1.24, 95% CI 1.14–1.35 for laryngeal cancer, and HR 1.30, 95% CI 1.22–1.38 for esophageal cancer) and smokers (HR 1.22, 95% CI 1.11–1.34 for oral cancer, HR 1.34, 95% CI 1.20–1.50 for laryngeal cancer, and HR 1.46, 95% CI 1.33–1.60 for esophageal cancer). We also estimated the risk of incident cancer in those with hypertension according to smoking and alcohol consumption. Among even non-drinkers and non-smokers, the HR for hypertension was 1.17 (95% CI 1.07–1.28) for esophageal cancer.

We examined the effect of BP categories at baseline on the risk of oral, laryngeal, and esophageal cancers (Table 4). A significant relationship between the risk of oral cancer and hypertension without medication (HR 1.15, 95% CI 1.05–1.26) was observed after adjusting for confounders. We observed an association between risk of laryngeal cancer and hypertension irrespective of medication (HR 1.25, 95% CI 1.09–1.44 for hypertension vs. 1.21, 95% CI 1.07–1.36 with medication). In esophageal cancer, the association was stronger for hypertension without medication (HR 1.47, 95% CI 1.31–1.66) compared to with medication (HR 1.33, 95% CI 1.18–1.50).

Table 2. Multivariable Cox proportional hazard model for incidence of oral, laryngeal, and esophageal cancer according to the metabolic syndrome. Model Adjusted for age, gender, smoking status, alcohol intake, exercise, and body mass index.

| Variables | Total Number | Oral cancer | Laryngeal cancer | Esophageal cancer |
|-----------|--------------|-------------|-----------------|------------------|
|           | No of cases  | Person-years| Annual incidence| Hazard ratio (95% CI) | No of cases  | Person-years| Annual incidence| Hazard ratio (95% CI) | No of cases  | Person-years| Annual incidence| Hazard ratio (95% CI) |
| Metabolic syndrome | | | | | | | | | | | | | |
| No        | 7,150,403   | 3,822       | 52,098,106      | 0.07336          | 1 (reference)   | 1,609       | 52,104,839      | 0.03088          | 1 (reference)   | 3,044       | 52,102,807      | 0.058423          | 1 (reference)   |
| Yes       | 2,596,042   | 2,240       | 18,778,185      | 0.11929          | 1.09 (1.03–1.16) | 1,049       | 18,781,282      | 0.055853          | 1.27 (1.17–1.38) | 1,708       | 18,780,664      | 0.090945          | 1.11 (1.04–1.19) |

Number of metabolic syndrome

| 0 | 2,521,362 | 911 | 18,440,641 | 0.0494 | 1 (reference) | 303 | 18,442,567 | 0.015429 | 1 (reference) | 506 | 18,442,286 | 0.02744 | 1 (reference) |
| 1 | 2,576,107 | 1,421 | 18,761,529 | 0.07574 | 1.04 (0.95–1.13) | 607 | 18,763,978 | 0.032349 | 1.14 (0.99–1.31) | 1,247 | 18,763,004 | 0.06646 | 1.39 (1.25–1.54) |
| 2 | 2,052,934 | 1,490 | 14,895,935 | 0.10003 | 1.12 (1.03–1.22) | 699 | 14,898,293 | 0.046918 | 1.35 (1.17–1.55) | 1,291 | 14,894,516 | 0.08666 | 1.49 (1.34–1.66) |
| 3 | 1,417,283 | 1,159 | 10,263,774 | 0.11292 | 1.14 (1.04–1.26) | 558 | 10,265,329 | 0.054358 | 1.48 (1.27–1.71) | 888 | 10,265,042 | 0.08651 | 1.43 (1.27–1.60) |
| 4 | 843,804   | 771 | 6,098,914 | 0.12642 | 1.19 (1.07–1.32) | 367 | 6,099,957 | 0.060164 | 1.63 (1.37–1.90) | 613 | 6,099,724 | 0.1005 | 1.65 (1.46–1.87) |
| 5 | 334,955   | 310 | 2,415,497 | 0.12834 | 1.22 (1.06–1.41) | 124 | 2,415,995 | 0.051325 | 1.65 (1.32–2.07) | 207 | 2,415,897 | 0.08568 | 1.72 (1.44–2.04) |

Figure 1. The risk of cancer according to the presence of hypertension. (A) Oral cancer, (B) Laryngeal cancer, (C) Esophageal cancer. The X-axis represents years, while the Y-axis represents the cumulative incidence probability of cancer occurrence.
Table 3. Multivariable Cox proportional hazard model for incidence of oral, laryngeal, and esophageal cancer according to the presence or absence of hypertension. *Model Adjusted for age, gender, smoking status, alcohol intake, exercise, body mass index, and diabetes.*

Impact of a combination of hypertension and diabetes on oral, laryngeal, and esophageal cancer incidence. Multivariable analyses revealed that participants with both hypertension and diabetes had the highest HR for oral cancer (HR 1.22; 95% CI 1.11–1.33), laryngeal cancer (HR 1.46; 95% CI 1.22–1.66), and esophageal cancer (HR 1.44; 95% CI 1.31–1.58) (Table 5). Participants with diabetes were also at significantly higher risk of laryngeal cancer (HR 1.20; 95% CI 1.02–1.42) and esophageal cancer (HR 1.19; 95% CI 1.05–1.35). In addition, subsample analysis demonstrated that men with both hypertension and diabetes had 1.23, 1.49, 1.51 times higher risk of oral cancer, laryngeal cancer, and esophageal cancer, respectively. Hypertension in combina-
Table 4. Multivariable Cox proportional hazard model for incidence of oral, laryngeal, and esophageal cancer according to the blood pressure categories. *Model* Adjusted for age, gender, smoking status, alcohol intake, exercise, body mass index, and diabetes.

| Blood pressure categories | Total number | Oral cancer | Laryngeal cancer | Esophageal cancer |
|---------------------------|--------------|-------------|-----------------|------------------|
|                           | No of cases  | Person-years | Annual incidence rates | Hazard ratio (95% CI) | No of cases  | Person-years | Annual incidence rates | Hazard ratio (95% CI) | No of cases  | Person-years | Annual incidence rates | Hazard ratio (95% CI) |
| Normotension              | 3,373,344    | 1,400       | 21,343,268      | 0.06559 1 (reference) | 484         | 21,345,599  | 0.022674 1 (reference) | 808         | 21,345,219  | 0.03785 1 (reference) |
| Prehypertension           | 3,891,818    | 2,127       | 24,550,213      | 0.08664 0.99 (0.92–1.06) | 873         | 24,553,015  | 0.035556 1.04 (0.93–1.17) | 1566        | 24,552,284  | 0.06378 1.13 (1.04–1.23) |
| Hypertension without medication | 857,819,857,819 | 738     | 5,368,896      | 0.13746 1.15 (1.05–1.26) | 355         | 5,369,624  | 0.066113 1.25 (1.09–1.44) | 710         | 5,369,221  | 0.13224 1.47 (1.33–1.63) |
| Hypertension with medication | 1,623,625    | 1,797       | 10,138,425      | 0.17725 1.07 (0.99–1.16) | 946         | 10,140,092  | 0.093293 1.26 (1.12–1.42) | 1668        | 10,139,377  | 0.16451 1.31 (1.20–1.43) |

Systolic blood pressure

|                          |             |             |                 |                 |             |             |                 |                 |
|-------------------------|-------------|-------------|-----------------|-----------------|
|                          |             |             |                 |                 |             |             |                 |                 |

Diastolic blood pressure

|                          |             |             |                 |                 |             |             |                 |                 |
|-------------------------|-------------|-------------|-----------------|-----------------|
|                          |             |             |                 |                 |             |             |                 |                 |

Systolic blood pressure (per 10 mmHg)

|                          |             |             |                 |                 |             |             |                 |                 |
|-------------------------|-------------|-------------|-----------------|-----------------|
|                          |             |             |                 |                 |             |             |                 |                 |

Diastolic blood pressure (per 10 mmHg)

|                          |             |             |                 |                 |             |             |                 |                 |
|-------------------------|-------------|-------------|-----------------|-----------------|
|                          |             |             |                 |                 |             |             |                 |                 |

Discussion

Results of this population study demonstrated the effect of hypertension and MetS on the development of oral, laryngeal, and esophageal cancers in a nationwide setting of nearly a quarter of the adult population in Korea. As far as we know, this study is one of the few that examined a massive and homogeneous nationwide population-based cohort. We demonstrated that hypertension and MetS had a significant linear relationship with the risk of oral, laryngeal, and esophageal cancers after adjusting for confounders such as gender, smoking status, alcohol intake, exercise, body mass index, and diabetes. MetS was associated with 9%, 27%, and 11% higher risk of developing oral, laryngeal, and esophageal cancers, respectively. Hypertension was also associated with risk of oral, laryngeal, and esophageal cancers. Both hypertension and prehypertension were associated with an increased risk of developing esophageal cancer. Although hypertension was most correlated with these three types of cancer, diabetes was also found to increase the risk of UADT cancers. The combined presence of hypertension and diabetes was associated with a higher risk estimate for each cancer, in people who were ex- or current smokers as well as in people who had never smoked. The smoking group with hypertension and diabetes was at a higher risk of oral cancer (HR 1.33, 95% CI 1.14–1.56), laryngeal cancer (HR 1.68, 95% CI 1.41–2.00), and esophageal cancer (HR 1.54, 95% CI 1.33–1.79) compared to the smoking group without hypertension or diabetes. Specifically, among even those who had never smoked, there was an association between hypertension in combination with diabetes and the risk of oral cancer (HR 1.17, 95% CI 1.04–1.31), laryngeal cancer (HR 1.23, 95% CI 1.06–1.52), and esophageal cancer (HR 1.35, 95% CI 1.20–1.53). The HR for hypertension and diabetes was 1.16 (95% CI 1.03–1.30) for oral cancer, 1.24 (95% CI 1.02–1.50) for laryngeal cancer, and 1.39 (95% CI 1.21–1.59) for esophageal cancer among non-smokers and non-drinkers.

Several recent observational studies have reported an association between hypertension and the development of UADT cancers. Some reports have linked anti-hypertensive drugs to the development of certain types of cancer. Calcium channel blockers have been correlated with cancer as they can affect cellular replication and apoptosis by interfering with calcium-mediated intracellular mechanisms. There are also reports that the use of diuretics could increase rates of various types of cancer, such as colorectal and breast cancers. The assertion that hypertension causes cancer is controversial, reports that hypertension can occur as a side effect of chemotherapy tend to be more reputable. Many anti-cancer drugs have been reported to cause arterial hypertension through different mechanisms.
| Variables | Oral Cancer | Laryngeal cancer | Esophageal cancer |
|-----------|-------------|-----------------|------------------|
|           | Non | Smoker | Non-smoker | Non-smoker and non-drinker |
| Total Number | 3,207 | 3,144 | 1,144 | 1,956 |
| No of cases | 69,07,641 | 1,13,457 | 19,09,354 | 48,31,627 |
| Person-years | 4,36,62,173 | 70,24,812 | 15,28,827 | 3,05,85,453 |
| Annual incidence rates | 0.07345 | 0.18506 | 0.09517 | 0.06395 |
| Hazard ratio (95% CI) | 1 (reference) | 1 (0.96–1.39) | 1 (reference) | 1 (0.96–1.39) |
| No of cases | 1,197 | 88 | 72 | 503 |
| Person-years | 4,36,67,030 | 7,02,563 | 15,29,021 | 3,05,89,199 |
| Annual incidence rates | 0.02741 | 0.12526 | 0.04709 | 0.01644 |
| Hazard ratio (95% CI) | 1 (reference) | 1 (0.98–1.54) | 1 (0.91–1.49) | 1 (0.96–1.34) |
| No of cases | 2,099 | 112 | 163 | 894 |
| Person-years | 4,36,66,008 | 7,02,563 | 15,28,908 | 3,05,88,699 |
| Annual incidence rates | 0.04807 | 0.15941 | 0.10661 | 0.02923 |
| Hazard ratio (95% CI) | 1 (reference) | 1 (0.87–1.28) | 1 (1.10–1.54) | 1 (1.13–1.62) |

Continued
chemotherapeutic drugs, anti-VEGF (vascular endothelial growth factors) drugs are most frequently involved in a rise in blood pressure levels mainly through decreased nitric oxide synthesis.

Development of oral squamous cell carcinoma is reportedly influenced by numerous factors, including tobacco, alcohol, diet and nutrition, viruses, radiation, ethnicity, familial and genetic predisposition, oral thrush, immunosuppression, use of mouthwash, syphilis, dental factors, occupational risks, and mate tea. Risk factors for the pathogenesis of laryngeal cancer are tobacco and alcohol consumption, red meat, and exposure to environmental factors such as asbestos, polycyclic aromatic hydrocarbons, and textile dust. The relationship between gastroesophageal reflux disease (GERD) and human papilloma virus in the development of laryngeal cancer is still controversial and under investigation. Risk factors for esophageal cancer are known to include alcohol, smoking, tea, mate tea, and coffee. Those for esophageal adenocarcinoma include GERD, Barrett's esophagitis, obesity, and smoking tobacco.

Although this study grouped oral, laryngeal, and esophageal cancers anatomically into the category of UADT cancer, these three cancers have distinct cell types. They are somewhat heterogenous histopathologically. Most oral and laryngeal cancers are squamous cell carcinoma, for which alcohol and smoking are risk factors. However, the majority of esophageal cancers are squamous cell carcinoma. Adenocarcinomas make up a significant proportion. They are especially predominant among white men. Studies have shown that one of the major risk factors for developing esophageal adenocarcinoma is GERD. Studies have also reported that GERD is more common in patients with hypertension. Drahos et al. reported that MetS is associated with an increased risk of developing esophageal adenocarcinoma in males without GERD and females regardless of GERD status using a SEER-Medicare-linked database. Thus, one can infer a relationship between hypertension and esophageal adenocarcinoma. However, this relationship has not yet been reported by the scientific community.

Our study has many strengths. First, participants comprised one-fourth of the adult Korean population. In addition, this longitudinal study followed participants for seven years, gathering data on cancer development. Second, the reliability of the data is strengthened by the accessibility of Korea's healthcare system, which covers all Korean citizens without exception. Third, study data only included cases of cancer that were diagnosed by a pathologist and types of hypertension were classified according to strict diagnostic criteria. Finally, BP was measured by skilled personnel and was not reported on its own. Detailed information on lifestyle, BMI, and laboratory test was also provided, enabling adjustments to potential confounding and shared risk factors.

### Table 5. Multivariable Cox proportional hazard model for incidence of oral, laryngeal, and esophageal cancer according to the condition of diabetes and hypertension. Model Adjusted for age, gender, smoking status, alcohol intake, exercise, and body mass index.

| Variables | Condition of diabetes/ hypertension | Total Number | Oral Cancer | Laryngeal cancer | Esophageal cancer |
|-----------|------------------------------------|--------------|-------------|-----------------|------------------|
|           | No of cases | Person-years | Annual incidence rates | Hazard ratio (95% CI) | No of cases | Person-years | Annual incidence rates | Hazard ratio (95% CI) | No of cases | Person-years | Annual incidence rates | Hazard ratio (95% CI) |
| Non-smoker and non-drinker | None | 1,66,610 | 107 | 10,53,266 | 0.10159 | 1 (reference) | 46 | 10,53,390 | 0.04367 | 1 (reference) | 195 | 10,53,103 | 0.18517 | 1 (reference) |
| | Diabetes | 12,369 | 18 | 77,163 | 0.23327 | 1.46 (0.88–2.42) | 6 | 77,189 | 0.07773 | 1.04 (0.44–2.44) | 28 | 77,146 | 0.36295 | 1.00 (0.79–1.26) |
| | Hypertension | 77,378 | 115 | 4,85,605 | 0.23682 | 1.35 (1.02–1.78) | 58 | 4,85,715 | 0.11941 | 0.39 (0.93–2.08) | 161 | 4,85,530 | 0.33160 | 0.83 (0.67–1.04) |
| | Hypertension and diabetes | 20,877 | 34 | 1,29,073 | 0.36342 | 1.29 (0.86–1.93) | 19 | 1,29,107 | 0.14716 | 1.52 (0.88–2.65) | 71 | 1,28,986 | 0.55044 | 1.21 (0.91–1.60) |
| Smoker and non-drinker | None | 16,36,555 | 935 | 1,03,04,131 | 0.09074 | 1 (reference) | 500 | 1,03,05,024 | 0.04852 | 1 (reference) | 735 | 1,03,04,978 | 0.07132 | 1 (reference) |
| | Diabetes | 94,386 | 100 | 5,84,526 | 0.17108 | 1.13 (0.92–1.39) | 72 | 5,84,571 | 0.12317 | 1.33 (1.04–1.70) | 76 | 5,84,630 | 0.13000 | 1.00 (0.79–1.27) |
| | Hypertension | 3,64,093 | 500 | 22,58,663 | 0.22117 | 1.29 (1.15–1.45) | 363 | 22,58,841 | 0.16070 | 1.40 (1.21–1.64) | 528 | 22,58,819 | 0.23375 | 1.48 (1.32–1.67) |
| | Hypertension and diabetes | 85,715 | 152 | 5,21,096 | 0.29169 | 1.33 (1.12–1.60) | 123 | 5,21,192 | 0.23600 | 1.56 (1.27–1.92) | 163 | 5,21,160 | 0.31276 | 1.58 (1.33–1.89) |
| Smoker and drinker | None | 2,72,780 | 209 | 17,14,735 | 0.12188 | 1 (reference) | 148 | 17,14,800 | 0.08631 | 1 (reference) | 275 | 17,14,653 | 0.16038 | 1 (reference) |
| | Diabetes | 19,068 | 30 | 1,17,665 | 0.25496 | 1.25 (0.85–1.84) | 16 | 1,17,702 | 0.13594 | 0.92 (0.55–1.54) | 36 | 1,17,666 | 0.30595 | 1.17 (0.82–1.65) |
| | Hypertension | 84,891 | 121 | 5,27,247 | 0.22949 | 1.02 (0.81–1.29) | 102 | 5,27,234 | 0.19346 | 1.15 (0.89–1.50) | 214 | 5,27,120 | 0.40598 | 1.38 (1.15–1.67) |
| | Hypertension and diabetes | 20,383 | 47 | 1,24,327 | 0.37803 | 1.32 (0.85–1.83) | 53 | 1,24,288 | 0.42643 | 2.02 (1.46–2.80) | 62 | 1,24,346 | 0.49861 | 1.43 (1.08–1.90) |
There were some limitations. First, data on UADT cancers classified by their ICD code did not include information on cancer cell types. As a result, we were unable to separately analyze cases of squamous cell carcinoma and adenocarcinoma. Second, we did not include detailed biochemical information about cancer stage, laryngoscopy findings, family history, or medication history. Third, the incidence of UADT cancers tended to peak between the ages of 60 and 70, but participants in our study were relatively young. Furthermore, mean age of group without hypertension is significantly younger than group with hypertension. For age difference of the two groups, we already statistically adjusted the effect of age. However, for the average age of whole study participants, it is absolutely shortcoming at a population-based study. Notwithstanding these limitations, it would not change the lesson of this study that patients diagnosed with hypertension, even at middle age, should give attention to the risk of UADT cancer. Fourth, our study was subject to the inherent limitations of its retrospective and observational design. We also thought that the follow-up time of this study was rather short to assess the risk of cancer development with improved accuracy. Lastly, we could not evaluate the entire Korean population and therefore our results may have been influenced by selection bias. In conclusion, this population-based study shows evidence of an association between hypertension/MetS and development of oral, laryngeal, and esophageal cancers. Further research on this subject may lead to recommendations that patients diagnosed with hypertension and MetS should undergo regular screenings for these cancers.

Materials and methods

Study population. The Korean National Health Insurance Service (KNHIS), the country’s public medical insurance system, is administered by the Ministry for Health, Welfare and Family Affairs\(^3\). Korean adults over 40 years of age and employees over 20 years of age receive regular health examinations every one or two years. Detailed information on this program is available in a previous paper\(^4\). Diagnoses were confirmed using the International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes. Oral, laryngeal, and esophageal cancers were defined as C00–C06, C32.0–32.9, and C15.0–C15.9, respectively. Written informed consent was provided by all participants. The study protocol was approved by the Institutional Review Board of the Catholic Medical Center. Methods were performed in accordance with relevant guidelines and regulations.

Patient selection. The development of oral, laryngeal, or esophageal cancer was assessed until 2016 using KNHIS claims records during the study period. Basic registration was conducted for participants who had been examined between January 1 and December 31, 2009 (n = 9,746,606) (Figure 2).

Blood pressure (BP) measurements were taken according to the Korean Society of Hypertension guidelines\(^5\). Briefly, after anthropometric measurements with at least 5 min rest, BP was measured more than twice using a mercury or automatic sphygmomanometer with the patient in a seated position. The measured BP was classified as normal SBP < 120 mmHg and DBP < 80 mmHg), prehypertension (SBP 120–139 mmHg or DBP 80–89 mmHg), or hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg)\(^5\). A positive antihypertensive medication history was defined as answering “Yes” to corresponding questions on the health screening questionnaire. The study population was classified into the following four subgroups based on blood pressure and antihypertensive medication history: 1. Normotensive without medication; 2. prehypertensive without medication; 3. hypertensive without medication; and 4. hypertensive with medication. Diabetes was defined as a fasting blood glucose level ≥ 7 mmol/L (≥ 126 mg/dL) or the presence of one or more claims per year for antihyperglycemic medications with ICD-10-CM code E10-14. Dyslipidemia was defined as a total cholesterol level ≥ 6.21 mmol/L (≥ 240 mg/dL) or the presence of one or more claims per year for antihyperlipidemic medications with ICD-10-CM code E78. Body mass index was calculated as weight in kilograms divided by the square of height in meters (kg/m²). Medical examinations included measurements of height, weight, and blood pressure, and laboratory tests. Health-related behaviors and past medical history such as smoking, alcohol consumption, and physical activity were collected using standardized self-reporting questionnaires.

The definition of MetS was based on the definition established by the joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention\(^6\). According to this institution, patients with MetS should have three or more of the following five components: abdominal obesity (≥ 90 cm for men and ≥ 85 cm for women), elevated blood pressure (systolic ≥ 130 and/or diastolic ≥ 85 mmHg), hyperglycemia (fasting plasma glucose ≥ 5.6 mmol/L (≥ 100 mg/dL)), hypertriglyceridemia (triglycerides ≥ 1.7 mmol/L (≥ 150 mg/dL)), and low HDL-cholesterol levels (1.0 mmol/L (< 40 mg/dL) for men and 1.3 mmol/L (< 50 mg/dL for women)\(^7\).

Statistical analysis. All statistical analyses were conducted using SAS software (version 9.2; SAS Institute, Cary, NC, USA). Baseline characteristics of study participants according to the presence of hypertension are presented as means ± standard deviations for continuous variables and numbers (percentages) for categorical variables. Values were compared using independent t-tests for continuous variables and chi-squared tests for categorical variables. Incidence rates of oral, laryngeal, esophageal cancers were calculated by dividing the number of events by 1,000 person-years. Cox proportional hazards analyses were performed to evaluate the association of MetS and hypertension with incidence of oral, laryngeal, or esophageal cancer. HRs and 95% CIs were calculated. Models were adjusted for smoking status, alcohol intake, exercise, body mass index, and diabetes. Kaplan–Meier curves were used to show the cumulative incidence probability of oral, laryngeal, or esophageal cancer. Log-rank tests were performed to examine the association of MetS and hypertension with the risk of oral, laryngeal, or esophageal cancer. A p-value < 0.05 was considered statistically significant.

https://doi.org/10.1038/s41598-020-67329-3
Figure 2. Study profile.

Received: 28 October 2019; Accepted: 7 June 2020
Published online: 24 June 2020

References
1. López-Pelayo, H. et al. Alcohol consumption in upper aerodigestive tract cancer: role of head and neck surgeons’ recommendations. Alcohol 51, 51–56 (2016).
2. Domper Arnal, M. J., Ferrandez Arenas, A. & Lanas, A. A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J. Gastroenterol. 21, 7933–7943 (2015).
3. Bellastella, G., Scappaticcio, L., Esposito, K., Giugliano, D. & Maiorino, M. I. Metabolic syndrome and cancer: "the common soil hypothesis". Diabetes Res. Clin. Pract. 143, 389–397 (2018).
4. Mendonça, F. M. et al. Metabolic syndrome and risk of cancer: which link?. Metabolism 64, 182–189 (2015).
5. Shin, J. et al. 2013 Korean Society of Hypertension guidelines for the management of hypertension: part I-epidemiology and diagnosis of hypertension. Clin. Hypertens. 21, 1 (2015).
6. Whelton, P. K. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guidelines for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice Guidelines. Hypertension 71, e13–e115 (2018).
7. Lee, H. Y. et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin. Hypertens. 25, 20 (2019).
8. Kocher, N. J., Rjepaj, C., Robyak, H., Lehman, E. & Raman, J. D. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J. Urol. 35, 67–72 (2017).
9. Stocks, T. et al. Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension 59, 802–810 (2012).
10. Seretis, A. et al. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Sci. Rep. 12(9), 8565 (2019).
11. Christakoudi, S. et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int. J. Cancer 15(146), 2680–2693 (2020).
12. Colt, J. S. et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 22, 797–804 (2011).
13. Corrao, G., Scotti, L., Bagnardì, V. & Sega, R. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr. Drug Saf. 2, 125–133 (2007).
14. Bangalore, S. et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12, 65–82 (2011).
15. Milan, A. et al. Arterial hypertension and cancer. Int J Cancer. 134, 2269–2277 (2014).
16. Radisauskas, R., Kuzmickiene, I., Milinaviciene, E. & Everett, R. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. *Medicina (Kaunas)* 52, 89–98 (2016).

17. Mason, R. P. Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. *Cancer* 85, 2093–2102 (1999).

18. Pahor, M. et al. Do calcium channel blockers increase the risk of cancer?. *Am. J. Hypertens.* 9, 695–699 (1996).

19. Grossman, E., Messerli, F. H. & Goldbourt, U. Does diuretic therapy increase the risk of renal cell carcinoma?. *Am. J. Cardiol.* 83, 1090–1093 (1999).

20. Jansen, L., Below, J., Chang-Claude, J., Brenner, H. & Hoffmeister, M. Beta blocker use and colorectal cancer risk: population-based case-control study. *Cancer* 118, 3911–3919 (2012).

21. Barron, T. I., Connolly, R. M., Bahn, J., Bennett, K. & Visvanathan, K. Beta blockers and breast cancer mortality: a population-based study. *J. Clin. Oncol.* 29, 2635–2644 (2011).

22. Michals, K. B. et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US women: the nurses’ health study. *Cancer* 83, 2003–2007 (1999).

23. Coleman, C. I., Baker, W. L., Kluger, J. & White, C. M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. *J. Hypertens.* 26, 622–629 (2008).

24. Pahor, M. et al. Do calcium channel blockers increase the risk of cancer?. *Am. J. Hypertens.* 8, 695–699 (1996).

25. Grossman, E., Messerli, F. H. & Goldbourt, U. Does diuretic therapy increase the risk of renal cell carcinoma?. *Am. J. Cardiol.* 83, 1090–1093 (1999).

26. Jansen, L., Below, J., Chang-Claude, J., Brenner, H. & Hoffmeister, M. Beta blocker use and colorectal cancer risk: population-based case-control study. *Cancer* 118, 3911–3919 (2012).

27. Barron, T. I., Connolly, R. M., Bahn, J., Bennett, K. & Visvanathan, K. Beta blockers and breast cancer mortality: a population-based study. *J. Clin. Oncol.* 29, 2635–2644 (2011).

28. Michals, K. B. et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US women: the nurses’ health study. *Cancer* 83, 2003–2007 (1999).

29. Coleman, C. I., Baker, W. L., Kluger, J. & White, C. M. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. *J. Hypertens.* 26, 622–629 (2008).

30. Pahor, M. et al. Do calcium channel blockers increase the risk of cancer?. *Am. J. Hypertens.* 8, 695–699 (1996).

31. Grossman, E., Messerli, F. H. & Goldbourt, U. Does diuretic therapy increase the risk of renal cell carcinoma?. *Am. J. Cardiol.* 83, 1090–1093 (1999).

Acknowledgements
This work was supported, in part, by grants from the Korean Society of Otorhinolaryngology-Head and Neck Surgery, 2018, and the alumni associated of the Department of Otolaryngology Head and Neck Surgery, The Catholic University of Korea, 2018.

Author contributions
J.H.S, Y.D.K., and C.S.P wrote the first draft of the manuscript. K.D.H. took part in the data analyses and performed statistical analyses. Y.H.J. designed the study and critically revised the manuscript for important intellectual content.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Y.-H.J.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020